PFIZER2022-01-012022-03-31in-bse-fin:OneOperatingExpenses01Member PFIZER2022-01-012022-03-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares PFIZER 2021-04-01 2022-03-31 2022-05-10 INR Crores Yearly true Cash Flow Indirect Single segment Pharmaceuticals 2022-01-01 2022-03-31 Audited Standalone 5496600000.00 171200000.00 5667800000.00 849800000.00 2073700000.00 -1026400000.00 923100000.00 38500000.00 336100000.00 1021900000.00 4216700000.00 1451100000.00 0.00 1451100000.00 406000000.00 -212800000.00 193200000.00 0.00 1257900000.00 0.00 0.00 0.00 0.00 1257900000.00 67200000.00 1325100000.00 0.00 0.00 457500000.00 10 27.50 27.50 0.00 0.00 27.50 27.50 1. The above results were reviewed and recommended by the Audit Committee for approval to the Board, at its Meeting held on May 20, 2022 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date. 2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). 3. The financial results for the year ended March 31, 2022 have been audited by the statutory auditors of the Company. The audit report does not contain any modifications. The audit report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerindia.com 4. Figures for the quarter ended March 31, 2022 and March 31, 2021 represent the difference between the audited figures in respect of the financial year and published figures of nine months ended December 31, 2021 and December 31, 2020 respectively which were subject to a limited review by the statutory auditors. 5. The Company has only one segment which is ‘Pharmaceuticals’. Therefore, disclosures relating to segments are not applicable and accordingly not made. 6. The Company has declared a Pfizer Voluntary Retirement Scheme 2022 (VRS) for eligible field employees in April 2022. This being a subsequent event, there is no financial impact for the year ended March 31, 2022. 7. The Company has monitored the impact of COVID-19 on all aspects of its business. The management has exercised due care, in concluding on significant accounting judgements and estimates, recoverability of receivables, assessment for impairment of goodwill, intangible assets, inventory based on the information available as on date, while preparing the financial results as of March 31, 2022. 8. The Board of Directors has recommended a dividend of Rs 35 per equity share of Rs 10 each (350%) for the year ended March 31, 2022. 9. The figures of the previous year / period have been regrouped / recast to render tham comparable with the figures of the current period. Single segment 2021-04-01 2022-03-31 Audited Standalone 26109900000.00 626500000.00 26736400000.00 3542900000.00 6666400000.00 -729000000.00 4036700000.00 104900000.00 1150000000.00 4235600000.00 19007500000.00 7728900000.00 0.00 7728900000.00 2183300000.00 -580000000.00 1603300000.00 0.00 6125600000.00 0.00 0.00 0.00 0.00 6125600000.00 71700000.00 6197300000.00 0.00 0.00 457500000.00 10 0.00 133.89 133.89 0.00 0.00 133.89 133.89 Other Expenses 1021900000.00 Other Expenses 4235600000.00 104900000.00 -138600000.00 -189100000.00 0.00 731500000.00 0.00 0.00 0.00 0.00 -111900000.00 0.00 0.00 70700000.00 1150000000.00 0.00 0.00 71200000.00 0.00 0.00 0.00 0.00 489400000.00 117700000.00 -86500000.00 0.00 0.00 -79700000.00 50300000.00 0.00 1201100000.00 8930000000.00 0.00 0.00 0.00 2259200000.00 0.00 6670800000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20600000.00 153100000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 437700000.00 0.00 -6055400000.00 0.00 -5750200000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1597400000.00 7800000.00 0.00 -199900000.00 -1805100000.00 -884500000.00 0.00 -884500000.00 1512100000.00 627600000.00